TICKERNERD
Menu
VMDVMDHealthcare · Medical Devices

VMD Stock Forecast: Viemed Healthcare, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$8.79
+0.46% on the day

The 2 Wall Street analysts covering Viemed Healthcare, Inc. hold a median 12-month price target of $13 — +42.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$334.8M
Ticker Nerd rank
93 / 100
Median analyst target
$13
Analysts covering
2
Revenue$78.1M+23.9% y/y
Operating income$5.1M
Net income$2.9M
Free cash flow$7.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.4%
1M
−5.3%
YTD
+18.3%
1Y
+27.0%
From 52W high
−28.7%
From 52W low
+40.4%
$6
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Viemed Healthcare, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
93 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
91
Quality
87
Volatility
79
Growth
75
Accruals
75
Momentum
69
Size
60
Issuance
59
Revisions
45

Value (91): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Revisions (45): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$6$8$10$12$14Oct 25Jan 26Apr 26Jul 26VMDHigh $14Median $13Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
1 Buy1 Hold0 Sell
Low $11Median $13High $14

The green dot is the last close — the median target sits +42.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Aug 2026Barrington ResearchInitiatesOutperform$14
6 Aug 2026Freedom BrokerDowngradeHold—
6 Aug 2026Freedom BrokerDowngradeHold$11
3 Nov 2021RBC CapitalMaintainsOutperform$13 → $9.00
3 Nov 2021RBC CapitalMaintainsOutperform—
5 Mar 2021RBC CapitalInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Viemed Healthcare, Inc. returned +27.0% against +17.5% for the S&P 500, dividends included.

VMD vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Oct 25Jan 26Apr 26Jul 26VMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−9.2%
Analysts raising
0
Analysts cutting
1
Fundamentals

Viemed Healthcare, Inc. (VMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
24.4×

Cheaper than 31% of US stocks

Price / sales
1.1×

Cheaper than 67% of US stocks

Price / book
2.3×

Cheaper than 41% of US stocks

EV / EBITDA
6.1×

Cheaper than 51% of US stocks

Growth & margins
Revenue growth (YoY)
23.9%

Higher than 73% of US stocks

Earnings growth (YoY)
−12.4%

Higher than 25% of US stocks

Gross margin
57.7%

Higher than 71% of US stocks

Operating margin
6.5%

Higher than 58% of US stocks

Net margin
4.8%

Higher than 59% of US stocks

Returns & dividend
Return on equity
10.5%

Higher than 64% of US stocks

Return on assets
8.2%

Higher than 88% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Viemed Healthcare, Inc. (VMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Viemed Healthcare, Inc. has a market value of $334.8M and an enterprise value of $337.7M.

  • Revenue in the twelve months to 30 June 2026: $301.6M. The latest quarter grew 23.9% year on year.

  • Net income over the same four quarters: $15.0M, a 5.0% net margin.

  • Diluted earnings per share, trailing twelve months: $0.36.

  • Free cash flow in the twelve months to 30 June 2026: $29.2M.

  • Viemed Healthcare, Inc. spent $20.5M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 38.1M.

  • Trailing P/E: 24.4×; forward P/E: 22.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Viemed Healthcare, Inc. employs 1,438 people — $210K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

VMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
VMDViemed Healthcare, Inc.$334.8M
93
MOBIMobia Medical, Inc.$331.2M
2
CVCapsoVision, Inc.$328.9M
20
CATXPerspective Therapeutics, Inc.$320.1M
30
OFIXOrthofix Medical, Inc.$353.6M
80
RCELAVITA Medical, Inc.$301.3M
66
SIShoulder Innovations, Inc.$385.8M
27

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Viemed Healthcare, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VMD news & analysis

Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands

MarketBeat · 29 Aug 2026positive

Viemed Healthcare presented its growth strategy, product diversification, and capital allocation priorities at the Midwest IDEAS Conference. The company emphasized its focus on providing in-home care for patients with complex respiratory conditions and targeting low-20% growth as the home ventilation opportunity expands.

Why it matters — VMD watchers would gain insight into the company's strategic direction, growth outlook, and capital allocation plans as it positions itself in the expanding home ventilation market.

Viemed Healthcare, Inc. (VMD) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Seeking Alpha published the transcript of Viemed Healthcare, Inc.'s Q2 2026 earnings call. The transcript covers management's discussion and Q&A from the quarterly earnings presentation.

Why it matters — VMD watchers can read the full transcript of the company's Q2 2026 earnings call to review management commentary on the quarter's results.

Viemed Healthcare Q2 Earnings Call Highlights

MarketBeat · 4 Aug 2026positive

Viemed Healthcare reported record second-quarter revenue, driven by resumed growth in its ventilator business under the updated Medicare coverage framework and expanded newer service lines.

Why it matters — A VMD watcher would care because record quarterly revenue signals renewed momentum in the core ventilator business and growth across newer service lines.

Viemed Healthcare, Inc. (VMD) Lags Q2 Earnings Estimates

Zacks Investment Research · 3 Aug 2026negative

Viemed Healthcare reported Q2 earnings of $0.07 per share, falling short of the Zacks Consensus Estimate of $0.10 per share and down from $0.08 per share a year ago.

Why it matters — The earnings miss versus analyst expectations and year-ago results may raise concerns about the company's near-term financial performance.

Viemed Healthcare Announces Second Quarter 2026 Financial Results

Accesswire · 3 Aug 2026positive

Viemed Healthcare reported financial results for the three and six months ended June 30, 2026. Net revenues for the quarter were $78.1 million, a Company record, up $15.0 million (23.9%) from the prior-year quarter and about 3.6% sequentially. The Company also updated its guidance for the full year ending December 31, 2026.

Why it matters — A VMD watcher would care because the quarter set a Company revenue record with significant year-over-year growth, and the Company revised its full-year 2026 outlook.

FAQ

Frequently asked questions about VMD stock

What is the VMD stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Viemed Healthcare, Inc. have a median 12-month price target of $13, with estimates ranging from $11 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VMD stock a buy right now?

Of the 2 analysts covering Viemed Healthcare, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Viemed Healthcare, Inc. 93 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VMD?

As at 12 Sept 2026, Viemed Healthcare, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (91 of 100).

Will VMD stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +42.2% from the last close, and Ticker Nerd's factor model ranks Viemed Healthcare, Inc. 93 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VMD stock forecast for 2030?

No analyst covering Viemed Healthcare, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $14 over the next 12 months.

How has VMD stock performed over the past year?

Viemed Healthcare, Inc. returned +27.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Viemed Healthcare, Inc. do?

Viemed Healthcare, Inc. is a healthcare company that provides home medical equipment and post-acute respiratory care services in the United States.

What is the latest news on VMD?

The most recent item we track (MarketBeat, 29 Aug 2026): "Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands". Viemed Healthcare presented its growth strategy, product diversification, and capital allocation priorities at the Midwest IDEAS Conference. The company emphasized its focus on providing in-home care for patients with complex respiratory conditions and targeting low-20% growth as the home ventilation opportunity expands.

Company

About Viemed Healthcare, Inc.

Viemed Healthcare, Inc. is a healthcare company that provides home medical equipment and post-acute respiratory care services in the United States. The company focuses on in-home treatment for patients with respiratory conditions, offering equipment, therapy support, and clinical services designed to help manage complex breathing disorders outside traditional hospital settings. Its current product and service portfolio includes non-invasive ventilation, oxygen equipment, sleep apnea testing and treatment, positive airway pressure therapy, respiratory disease management, and related supplies and support services. Viemed also provides complementary clinical and staffing services that support patient care in the home. The company serves patients nationwide and operates within the broader home healthcare and durable medical equipment markets, where it plays a specialized role in respiratory-focused in-home care.

CEO Mr. Casey Hoyt · 1,438 employees · United States · https://www.viemed.com